BioAdaptives Launches MyndMed Cognitive Supplement Following Positive Testing Results
BioAdaptives has commercially launched MyndMed, a cognitive-support dietary supplement designed to enhance memory and focus, representing the company's expansion into the growing brain health market with a product backed by positive user feedback and clinical research.
BioAdaptives, Inc. (OTCMKTS: BDPT) has announced the commercial launch of MyndMed, a next-generation dietary supplement formulated to enhance memory, focus, and overall brain performance. The company is scaling production and expanding distribution to meet anticipated high demand beginning in November following extensive testing that yielded highly positive user feedback.
The supplement is designed to support cognitive function across short-, mid-, and long-term pathways through clinically studied ingredients that promote alertness, neuroplasticity, and cellular energy balance. Marketed as providing "Mental Armor for Modern Minds," MyndMed is manufactured in cGMP-certified facilities in the United States and undergoes third-party testing for purity assurance.
MyndMed is now available nationwide through the company's official website at https://www.MyndMed.com. The launch represents BioAdaptives' continued expansion in the natural health and wellness sector, where the company develops science-based products for both humans and animals.
BioAdaptives leverages cutting-edge research in stem cell biology, adaptogens, and regenerative nutrition across its product portfolio. The company's mission focuses on enhancing quality of life through innovation that works in harmony with the body's natural processes. Additional information about the company is available at https://www.bioadaptives.com.
The press release announcing the MyndMed launch was distributed through InvestorWire, a specialized communications platform that provides advanced wire-grade press release syndication services. InvestorWire is part of the Dynamic Brand Portfolio at IBN, which includes more than 70 brands and offers comprehensive corporate communications solutions including article syndication to over 5,000 outlets and social media distribution to millions of followers.
For those seeking additional details about the MyndMed launch, the full press release can be accessed at https://ibn.fm/2isuA. InvestorWire's complete platform information and service details are available at https://www.InvestorWire.com, where full terms of use and disclaimers applicable to all content provided by the platform are also published.